Mi-Helper Transnasal Cooling for Acute Treatment of Migraine

Last updated: September 25, 2024
Sponsor: CoolTech LLC
Overall Status: Completed

Phase

N/A

Condition

Pain (Pediatric)

Migraine (Adult)

Migraine (Pediatric)

Treatment

Mi-Helper

Clinical Study ID

NCT06051604
COT-001
  • Ages 18-65
  • All Genders

Study Summary

This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting.

Adults aged 18 years to 65 years old with a diagnosis of episodic migraine (with or without aura) for at least one year (self-reported) will be recruited for this study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age of 18 to 65 years, inclusive of either sex at birth.

  2. Lives in the contiguous United States.

  3. Self-reported to be able to read and understand English sufficiently to provideinformed consent.

  4. Individual has had a diagnosis of episodic migraine with or without aura over atleast 1 year, self-reported during screening.

  5. Individual experiences 2 to 8 migraine attacks per month documented via migraineeDiary during screening.

  6. Individual is in good reported general health at the time of screening.

  7. Migraine onset before 50 years of age, self-reported during screening.

  8. Migraine prophylaxis medication unchanged for 4 weeks prior to study enrollment.

  9. Stated willingness to comply with all study procedures and availability for theduration of the study.

  10. Individuals that own a functioning smartphone device, internet connection (Wi-Fi ordata plan) and are willing to download the study app.

Exclusion

Exclusion Criteria:

  1. Participant has difficulty distinguishing his or her migraine attacks fromtension-type headaches.

  2. Participant has 15 or more headache days per month reported via migraine eDiary andduring screening.

  3. Participant using any opioid medication at the time of screening.

  4. Participant has received Botox treatment, barbiturates, supraorbital or occipitalnerve blocks within the last 4 weeks of screening.

  5. Participant lives at an altitude of 2000 meters or more above sea level.

  6. Self-reported intolerance to intranasal therapy.

  7. Self-reported recurrent epistaxis or chronic rhinosinusitis.

  8. Self-reported sinus or intranasal surgery within the last 4 months of screening.

  9. Self-reported history of 'complicated migraine or headaches' (i.e., hemiplegicmigraine, ophthalmoplegic migraine, migrainous infarction, basilar migraine,post-traumatic headaches, post-concussion syndrome).

  10. Known or suspected pregnancy as self-reported by the prospective participant at thetime of screening.

  11. Prospective participant unable to fully understand the consent process and provideinformed consent due to either language barriers or mental capacity.

  12. Self-reported diagnosis of alcohol or substance abuse disorder at the time ofscreening.

  13. Participant with active chronic pain syndromes, such as fibromyalgia, chronic pelvicpain, or complex regional pain syndrome (CRPS); or other pain syndrome liketrigeminal neuralgia.

  14. Participant with severe psychiatric conditions (such as major depressive episode,bipolar disorder, major depressive disorder, schizophrenia), dementia, orsignificant neurological disorders (other than migraine) that, in the Investigator'sopinion, might interfere with study assessments.

  15. Failure to adhere to or inability to complete Study App inputs and onboardingactivities during the screening period. Participants who are not adherent during thescreening period are not eligible for study entry.

  16. Prospective participant has participated in a migraine study or any interventionalclinical study within the 6 months prior to screening.

Study Design

Total Participants: 172
Treatment Group(s): 1
Primary Treatment: Mi-Helper
Phase:
Study Start date:
November 15, 2023
Estimated Completion Date:
September 24, 2024

Connect with a study center

  • ObvioHealth

    New York, New York 10001
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.